Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE)

Journal of Dermatological Treatment

Volumn 15, Issue 1, 2004, Pages 46-50

  Goodfield, Mark J D ^a   Davison, K ^a   Bowden, K ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Cutaneous lupus erythematosus; Intravenous immunoglobulin

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETRETIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; THALIDOMIDE;

ADULT; ARTICLE; ASEPTIC MENINGITIS; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG COST; FEMALE; HUMAN; HYPONATREMIA; IMMUNOTHERAPY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; TOXIC HEPATITIS; TREATMENT OUTCOME; VASCULITIS;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 1342290815     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630310018789     Document Type: Article

References (23)

1. Goodfield MJD, Rowell NR. The connective tissue diseases. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Rook's Textbook of Dermatology, 6th edn, Blackwell Science: Oxford, 1998: 2437-575.
2. Schulz EJ, Menker MA. Treatment of discoid and subacute lupus erythematosus with cyclophosphamide. Br J Dermatol (1971) 85: 60-5.
3. Schiller B, Elinder G. Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment. Acta Paediatr (1999) 88: 844-8.
4. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet (1997) 350: 620-3.
5. Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol (1999) 26: 457-9.
6. Marie I, Hachulla E, Levesque H et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol (1999) 26: 2706-9.
7. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med (1993) 329: 1993-2000.
8. Casado-Burgos E, Navarro T, Olive A, Ribera JM. Treatment with intravenous immunoglobulin in pure red cell aplasia in patients with systemic lupus erythematosus. Med Clin (Barc) (1999) 112: 678-82.
9. Lesprit P, Mouloud F, Bierling P et al. Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scand J Rheumatol (1996) 25: 177-9.
10. Sherer Y, Levy Y, Langevitz P et al. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol (1999) 18: 170-3.
11. Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus (1999) 8: 705-12.
12. De-Pita O, Bellucci AM, Ruffelli M et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus (1997) 6: 415-17.
13. Rutter A, Luger TA. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr Opin Invest Drugs (2002) 3: 713-19.
14. Sati HI, Ahya R, Watson HG. Incidences and associations of acute renal failure complicating high dose IVIg therapy. Br J Haematol (2001) 113: 556-7.
15. Genereaun T, Chosidow O, Danel C et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol (1999) 135: 1124-5.
16. Fredriksson T, Petterson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica (1978) 157: 238-44.
17. Picton P, Chisholm M. Aseptic meningitis associated with high dose immunoglobulin: case report. Br Med J (1997) 315: 1203-4.
18. Berger A, Scharrer I, Doerr HW et al. Infection with hepatitis C virus in immunoglobulin recipients. Lancet (1997) 349: 207.
19. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol (1998) 134: 80-6.
20. Parkes PJ, Lovell DJ. Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol (1996) 14: 673-5.
21. Ng SK. Intravenous immunoglobulin infusion causing pseudohyponatremia. Lupus (1999) 8: 488-90.
22. Klassen LW, Calabrese LH, Laxer RM. Intravenous immunoglobulin in rheumatic disease. Rheum Dis Clin North Am (1996) 22: 155-73.
23. Amemiya K, Semino-Mora C, Granger RP, Dalakas C. Downregulation of TGF-β mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol (2000) 94: 99-104.